Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics

View Full Paper
Ask AI
Bookmark
Share

Authors

DMDawn MazeASAaron D. SchimmerGRGuillaume Richard‐Carpentier

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows no significant survival benefit of gemtuzumab ozogamicin in AML, indicating similar outcomes for adverse events.

Key Points

  • This study aimed to assess the safety and efficacy of intensive chemotherapy with and without gemtuzumab ozogamicin in acute myeloid leukemia patients.
  • Retrospective analysis of adult patients at a cancer center between 2018 and 2024.
  • Comparison of 7+3 chemotherapy alone versus 7+3 with gemtuzumab ozogamicin using propensity score matching.
  • Endpoints included complete remission rates, MRD negativity, overall survival, and adverse events.
  • 90% complete remission rate in 7+3+GO group versus 77% in 7+3 group.
  • 81% MRD negativity in 7+3+GO group compared to 58% in 7+3 group.
  • Similar 2-year overall survival rates between both groups; significant adverse events more common with GO.

Cite This Study

Maze et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e030https://doi.org/10.1182/blood-2025-5240
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients2024 · 2 citations
  2. 2Initial results from a phase 2 study of cladribine, cytarabine, and granulocyte-colony stimulating factor with gemtuzumab ozogamicin (CLAG-GO) for the treatment of patients with relapsed/refractory acute myeloid leukemia2025
  3. 3Safety outcomes in patients with acute myeloid leukemia receiving gemtuzumab ozogamicin and proceeding to allogeneic hematopoietic stem cell transplantation.2024
  4. 4Combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory (R/R) Acute Myeloid Leukemia and post-hypomethylating agent (HMA) failure high-risk myelodysplastic syndrome (HR-MDS)2025
  5. 5Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT.2024